Case 09
PE-backed healthcare AI
Board & Investor
Governed clinical agents in production
Two governed agents deployed into clinical production
Technical mechanism: Interim CTO leadership, principal AI engineering, Agentic AI architecture, agent harness, clinical deployment, evals, and trust controls
2 agents
Clinical deployment
governed agents deployed into clinical production
View case details Hide case details
Case 09
PE-backed healthcare AI
Board & Investor
Governed clinical agents in production
Two governed agents deployed into clinical production
Technical mechanism: Interim CTO leadership, principal AI engineering, Agentic AI architecture, agent harness, clinical deployment, evals, and trust controls
2 agents
Clinical deployment
governed agents deployed into clinical production
View case details Hide case detailsBusiness situation
A late-stage healthcare AI company had meaningful demand and proprietary clinical-workflow data, but fragmented architecture, uneven release discipline, vendor dependency, weak observability and evaluation, and unclear platform ownership constrained safe clinical deployment and created material scale and diligence risk.
The board, investors, and executive team needed to prove that agents could operate safely in live clinics, earn healthcare-system trust, and scale on an architecture the company could govern and own.
Business objective
Deploy governed agents into clinical production while converting proprietary data and workflow advantages into an investor-ready platform with durable operating control and internal ownership.
Two governed agents reached clinical production and earned healthcare-system trust. Under Bottega8’s interim CTO, principal AI engineering, and Agentic AI architecture leadership, the company also became auditable, investor-ready, and able to own the system as durable IP.
Intervention sequence
- 01 Bottega8 served as interim CTO and led principal AI engineering and Agentic AI architecture across the transformation.
- 02 Ran principal-level diligence across code, architecture, security, data, product, talent, vendors, delivery economics, and the operating model.
- 03 Translated the findings into board decisions, investment priorities, architecture sequencing, accountable owners, and an execution roadmap.
- 04 Built the vertically optimized agent harness and reference architecture around governed state, observability, evals, human controls, release discipline, replay, and auditability.
- 05 Deployed governed agent workflows into clinic production and established the evidence, escalation, and operating controls required for healthcare-system trust.
- 06 Established an engineering-health system, directed the vendor transition, clarified platform ownership, and defined the senior hiring plan required for durable internal control.
- Independent diligence
- Board decisions
- Agent harness
- Evals + trust controls
- Clinic deployment
- Engineering health
- Vendor transition
- Platform ownership
The production agent system, clinical trust model, investment narrative, and ownership plan became one execution program.
Starting point
Meaningful demand and proprietary workflow data constrained by deployment, scale, and diligence risk
Intervention
Interim CTO leadership, principal AI engineering, Agentic AI architecture, agent harness, clinical deployment, evals, and trust controls
Measurement context
Documented production engagement, deployed Agentic AI in clinics across the US
Executive implication: Clinical agent systems earn institutional trust when production architecture, evals, evidence, human controls, board decisions, operating discipline, and permanent ownership reinforce one another.